Astex Pharmaceuticals to Present at AACR-NCI-EORTC

Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery and development of novel therapeutics, announced the acceptance of four abstracts detailing recent work with Astex Pharmaceuticals compounds. Poster presentations will occur on November 13, 14 and 15, 2011 at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, California.

The presentations will review pre-clinical advances with AT13387 (HSP90 inhibitor), PKM2 (Pyruvate Kinase) activators, FGFR (Fibroblast Growth Factor Receptor) inhibitor, and second generation PIM Kinase inhibitors. Select posters will be made available for viewing on the company’s website www.astx.com following the public presentation.

Sunday, Nov 13, 2011 12:30 – 2:30 pm PT
Abstract & Poster #: A217
The HSP90 inhibitor, AT13387, demonstrates potent anti-tumor activity in both imatinib-sensitive and imatinib-resistant gastrointestinal stromal tumor models

Monday, Nov 14, 2011 12:30 – 2:30 pm PT
Abstract & Poster #: B143
PKM2 metabolic activator slows lung cancer xenograft growth

Tuesday, Nov 15, 2011 12:30 – 2:30 pm PT
Abstract & Poster # C12
Identification of predictive and pharmacodynamic biomarkers for an FGFR receptor inhibitor

Tuesday, Nov 15, 2011 12:30 – 2:30 pm PT
Abstract & Poster # C200
Second generation PIM inhibitors exhibit improved activity in solid tumor models

About Astex Pharmaceuticals

Astex Pharmaceuticals is dedicated to the discovery and development of novel therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals, formerly SuperGen, developed Dacogen® (decitabine) for Injection and receives significant royalties on global sales.

For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.